Kymera Therapeutics Interest Expense 2011-2026 | KYMR

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Kymera Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
38 M	37.8 M	18.6 M	6.45 M	313 K	711 K	959 K	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
38 M	313 K	14.7 M

Quarterly Interest Expense Kymera Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
10.3 M	7.94 M	8.84 M	-	9.64 M	8.86 M	9.27 M	-	4.64 M	4.58 M	4.4 M	-	1.88 M	553 K	249 K	-	55 K	70 K	94 K	-	97 K	203 K	315 K	-	441 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
10.3 M	55 K	3.82 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Amphastar Pharmaceuticals AMPH	23 K	$ 21.91	2.34 %	$ 1.02 B	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	1.82 M	$ 22.7	3.37 %	$ 3.76 B	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	8 K	-	-	$ 28.6 M	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Brainstorm Cell Therapeutics BCLI	-93 K	-	-2.5 %	$ 5.88 M	USA
Applied Therapeutics APLT	-27 K	-	-	$ 8.42 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
BioNTech SE BNTX	14.2 M	$ 102.78	-2.55 %	$ 27.2 B	Germany
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Aquestive Therapeutics AQST	6.55 M	$ 4.16	1.84 %	$ 445 M	USA
Arcutis Biotherapeutics ARQT	443 K	$ 23.75	2.09 %	$ 3.02 B	USA
Autolus Therapeutics plc AUTL	36.7 M	$ 1.45	0.35 %	$ 386 M	Britain
Can-Fite BioPharma Ltd. CANF	227 K	$ 3.03	4.12 %	$ 4.99 M	Israel
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
bluebird bio BLUE	16.4 M	-	-	$ 546 M	USA
ContraFect Corporation CFRX	-4.81 M	-	-5.16 %	$ 5.39 M	USA
Cardiff Oncology CRDF	5 K	$ 1.76	2.03 %	$ 118 M	USA
BioXcel Therapeutics BTAI	-3.52 M	$ 1.11	4.25 %	$ 13.6 M	USA
Cabaletta Bio CABA	2 M	$ 3.02	2.43 %	$ 303 M	USA
Cara Therapeutics CARA	7.16 M	-	-3.03 %	$ 260 M	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
CASI Pharmaceuticals CASI	2.9 K	-	-	$ 35.4 M	USA
CymaBay Therapeutics CBAY	18.9 M	-	-	$ 3.45 B	USA